Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma

NCT01900496 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Lymphoma

Interventions

BIOLOGICAL: Brentuximab vedotin
BIOLOGICAL: Rituximab

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]